Lise E. Nigrovic M.D. M.P.H.

Dr. Lise E. Nigrovic M.D. M.P.H.

orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2007 in JAMA
Verified
Journal Article
Open access
PDF file
LMLise E. Nigrovic M.D. M.P.H.
Lise E. Nigrovic M.D. M.P.H.
Although bacterial meningitis is the greatest concern when evaluating and treating children with cerebrospinal fluid (CSF) pleocytosis,1 the majority of these children have aseptic rather than bacterial meningitis.2,3 However, because exclusion of bacterial meningitis requires negative CSF (and blood) cultures after 2 to 3 days of incubation,4,5 most children with CSF pleocytosis are admitted to the hospital to receive broad-spectrum antibiotics while awaiting culture test results. With the widespread introduction of highly effective bacterial conjugate vaccines against Haemophilus influenzae type b6,7 and Streptococcus pneumoniae,8-12 there has been a significant decrease in the incidence of bacterial meningitis in US children. This has further reduced the probability that a child with CSF pleocytosis will have bacterial meningitis. A highly accurate decision support tool that could identify which children with CSF pleocytosis had a near-zero risk of bacterial meningitis by using clinical and laboratory parameters readily available at the time of clinical presentation could guide decision making and limit unnecessary hospital admissions and prolonged antibiotic use.

1 October 2014 in Pediatrics
Verified
Journal Article
Closed access
PDF file
PAPaul L. Aronson
Paul L. Aronson
CTCary Thurm
Cary Thurm
EAElizabeth R. Alpern
Elizabeth R. Alpern
EAEvaline A. Alessandrini
Evaline A. Alessandrini
DWDerek J. Williams
Derek J. Williams
MNMark I. Neuman
Mark I. Neuman
BACKGROUND AND OBJECTIVES: Variation in patient care or outcomes may indicate an opportunity to improve quality of care. We evaluated the variation in testing, treatment, hospitalization rates, and outcomes of febrile young infants in US pediatric emergency departments (EDs). METHODS: Retrospective cohort study of infants <90 days of age with a diagnosis code of fever who were evaluated in 1 of 37 pediatric EDs between July 1, 2011 and June 30, 2013. We assessed patient- and hospital-level variation in testing, treatment, and disposition for patients in 3 distinct age groups: ≤28, 29 to 56, and 57 to 89 days. We also compared interhospital variation for 3-day revisits and revisits resulting in hospitalization. RESULTS: We identified 35 070 ED visits that met inclusion criteria. The proportion of patients who underwent comprehensive evaluation, defined as urine, serum, and cerebrospinal fluid testing, decreased with increasing patient age: 72.0% (95% confidence interval [CI], 71.0–73.0) of neonates ≤28 days, 49.0% (95% CI, 48.2–49.8) of infants 29 to 56 days, and 13.1% (95% CI, 12.5–13.6) of infants 57 to 89 days. Significant interhospital variation was demonstrated in testing, treatment, and hospitalization rates overall and across all 3 age groups, with little interhospital variation in outcomes. Hospitalization rate in the overall cohort did not correlate with 3-day revisits (R2 = 0.10, P = .06) or revisits resulting in hospitalization (R2 = 0.08, P = .09). CONCLUSIONS: Substantial patient- and hospital-level variation was observed in the ED management of the febrile young infant, without concomitant differences in outcomes. Strategies to understand and address the modifiable sources of variation are needed.

23 August 2016 in JAMA
Verified
Journal Article
Open access
PDF file
PMPrashant Mahajan
Prashant Mahajan
NKNathan Kuppermann
Nathan Kuppermann
AMAsuncion Mejias
Asuncion Mejias
NSNicolas Suarez
Nicolas Suarez
DCDamien Chaussabel
Damien Chaussabel
F(for the Pediatric Emergency Care Applied Research Network (PECARN)
for the Pediatric Emergency Care Applied Research Network (PECARN)
Febrile infants aged 60 days or younger are at substantial risk of serious bacterial infections (defined as bacteremia, urinary tract infections [UTIs], and bacterial meningitis), estimated at 7% to 9% in this population.1 Current guidelines recommend obtaining blood, urine, and cerebrospinal fluid (CSF) cultures, with consideration of antibiotic treatment and hospitalization until culture results are negative. Although these strategies aim to identify and treat all young febrile infants with serious bacterial infections, the costs and risks are high.2 The lack of an optimal management strategy has led to substantial variation in the care for this vulnerable population, unnecessarily exposing many infants to potential harm.

14 June 2018 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
NKNathan Kuppermann
Nathan Kuppermann
SGSimona Ghetti
Simona Ghetti
JSJeff E. Schunk
Jeff E. Schunk
MSMichael J. Stoner
Michael J. Stoner
ARArleta Rewers
Arleta Rewers
NGNicole Glaser
Nicole Glaser
Diabetic ketoacidosis in children may cause brain injuries ranging from mild to severe. Whether intravenous fluids contribute to these injuries has been debated for decades. We conducted a 13-center, randomized, controlled trial that examined the effects of the rate of administration and the sodium chloride content of intravenous fluids on neurologic outcomes in children with diabetic ketoacidosis. Children were randomly assigned to one of four treatment groups in a 2-by-2 factorial design (0.9% or 0.45% sodium chloride content and rapid or slow rate of administration). The primary outcome was a decline in mental status (two consecutive Glasgow Coma Scale scores of <14, on a scale ranging from 3 to 15, with lower scores indicating worse mental status) during treatment for diabetic ketoacidosis. Secondary outcomes included clinically apparent brain injury during treatment for diabetic ketoacidosis, short-term memory during treatment for diabetic ketoacidosis, and memory and IQ 2 to 6 months after recovery from diabetic ketoacidosis. A total of 1389 episodes of diabetic ketoacidosis were reported in 1255 children. The Glasgow Coma Scale score declined to less than 14 in 48 episodes (3.5%), and clinically apparent brain injury occurred in 12 episodes (0.9%). No significant differences among the treatment groups were observed with respect to the percentage of episodes in which the Glasgow Coma Scale score declined to below 14, the magnitude of decline in the Glasgow Coma Scale score, or the duration of time in which the Glasgow Coma Scale score was less than 14; with respect to the results of the tests of short-term memory; or with respect to the incidence of clinically apparent brain injury during treatment for diabetic ketoacidosis. Memory and IQ scores obtained after the children’s recovery from diabetic ketoacidosis also did not differ significantly among the groups. Serious adverse events other than altered mental status were rare and occurred with similar frequency in all treatment groups. Neither the rate of administration nor the sodium chloride content of intravenous fluids significantly influenced neurologic outcomes in children with diabetic ketoacidosis. (Funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the Health Resources and Services Administration; PECARN DKA FLUID ClinicalTrials.gov number, NCT00629707.)

1 September 2012 in Annals of Emergency Medicine
Verified
Journal Article
Closed access
BKBenjamin T. Kerrey
Benjamin T. Kerrey
ARAndrea S. Rinderknecht
Andrea S. Rinderknecht
GGGary L. Geis
Gary L. Geis
LMLise E. Nigrovic M.D. M.P.H.
Lise E. Nigrovic M.D. M.P.H.
MMMatthew R. Mittiga
Matthew R. Mittiga

1 October 2008 in Pediatrics
Verified
Journal Article
Closed access
PDF file
LMLise E. Nigrovic M.D. M.P.H.
Lise E. Nigrovic M.D. M.P.H.
RMRichard Malley
Richard Malley
CMCharles G. Macias
Charles G. Macias
JKJohn T. Kanegaye
John T. Kanegaye
DMDonna M. Moro-Sutherland
Donna M. Moro-Sutherland
NKNathan Kuppermann
Nathan Kuppermann
OBJECTIVE. The goal of this study was to evaluate the effect of antibiotic administration before lumbar puncture on cerebrospinal fluid profiles in children with bacterial meningitis.METHODS. We reviewed the medical records of all children (1 month to 18 years of age) with bacterial meningitis who presented to 20 pediatric emergency departments between 2001 and 2004. Bacterial meningitis was defined by positive cerebrospinal fluid culture results for a bacterial pathogen or cerebrospinal fluid pleocytosis with positive blood culture and/or cerebrospinal fluid latex agglutination results. Probable bacterial meningitis was defined as positive cerebrospinal fluid Gram stain results with negative results of bacterial cultures of blood and cerebrospinal fluid. Antibiotic pretreatment was defined as any antibiotic administered within 72 hours before the lumbar puncture.RESULTS. We identified 231 patients with bacterial meningitis and another 14 with probable bacterial meningitis. Of those 245 patients, 85 (35%) had received antibiotic pretreatment. After adjustment for patient age, duration and severity of illness at presentation, and bacterial pathogen, longer duration of antibiotic pretreatment was not significantly associated with cerebrospinal fluid white blood cell count, cerebrospinal fluid absolute neutrophil count. However, antibiotic pretreatment was significantly associated with higher cerebrospinal fluid glucose and lower cerebrospinal fluid protein levels. Although these effects became apparent earlier, patients with ≥12 hours of pretreatment, compared with patients who either were not pretreated or were pretreated for <12 hours, had significantly higher median cerebrospinal fluid glucose levels (48 mg/dL vs 29 mg/dL) and lower median cerebrospinal fluid protein levels (121 vs 178 mg/dL).CONCLUSIONS. In patients with bacterial meningitis, antibiotic pretreatment is associated with higher cerebrospinal fluid glucose levels and lower cerebrospinal fluid protein levels, although pretreatment does not modify cerebrospinal fluid white blood cell count or absolute neutrophil count results.